With most myelofibrosis patients becoming anemic over time, Ojjaara's approval represents a significant milestone to improve the outcomes of these patients while also highlighting GSK's commitment ...

In closing its therapeutics division and laying off 200 people, 23andMe ended an audacious bet it made nearly a decade ago — ...

The coveted designation for GSK5764227 (GSK'227, previously known as HS-20093) is for the use of the ADC to treat relapsed or refractory extensive-stage small-cell lung cancer (SCLC) and comes ...

The FDA updated GLP-1 drug labels to warn of the risk of patients breathing food into their lungs while under anesthesia for ...

GSK’s Trelegy, a treatment for chronic obstructive pulmonary disease (COPD), aimed to address a gap in the market with its ...

DelveInsight's 'NK Cell Therapy Pipeline Insight 2024' report provides comprehensive global coverage of pipeline NK cell ...

The print ads featured a prominent display of a person’s back, highlighting where shingles rashes typically emerge.

Hoos is leaving GSK after nine years, a period that saw a complete revamp of the unit including the wholesale divestment of cancer drugs to Novartis in a $16 billion deal announced in 2014 ...

In November, presented data from Study 0169 at the 2024 American Autonomic Society meeting highlighting the significant ... receives $240 million or more in royalty payments from GSK based on 2024 ...

We’re pleased to present the 2024 Top 50 State Lobbyists. Featured Article: Championing Inclusivity: Expanding Pathways to ...

Nov. 11, 2024 — A team of scientists has used a novel approach to identify protein degraders that target Pin1, a protein involved in pancreatic cancer ... DNA Packaging Directly Affects How Fast ...